{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T11:14:43Z","timestamp":1784805283323,"version":"3.55.0"},"reference-count":94,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010029","name":"Taishan Scholar Foundation of Shandong Province","doi-asserted-by":"publisher","award":["tsqn201812140"],"award-info":[{"award-number":["tsqn201812140"]}],"id":[{"id":"10.13039\/501100010029","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009108","name":"Shandong University","doi-asserted-by":"publisher","award":["6010225019"],"award-info":[{"award-number":["6010225019"]}],"id":[{"id":"10.13039\/100009108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ejphar.2026.178812","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T08:03:08Z","timestamp":1774598588000},"page":"178812","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Precision targeting of CD38 in immune thrombocytopenia: Mechanistic foundations and therapeutic implications"],"prefix":"10.1016","volume":"1021","author":[{"given":"Xin","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peipei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningning","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ejphar.2026.178812_bib1","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/cyto.a.23693","article-title":"High-parameter mass cytometry evaluation of relapsed\/refractory multiple myeloma patients treated with daratumumab demonstrates immune modulation as a novel mechanism of action","volume":"95","author":"Adams","year":"2019","journal-title":"Cytometry. Part A: The Journal of the International Society for Analytical Cytology"},{"issue":"6","key":"10.1016\/j.ejphar.2026.178812_bib2","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1182\/blood.2022018071","article-title":"Human CD34+ hematopoietic stem cell hierarchy: how far are we with its delineation at the Most primitive level?","volume":"142","author":"Anjos-Afonso","year":"2023","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.ejphar.2026.178812_bib3","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1217374","article-title":"Immunotherapies targeting CD38 in multiple myeloma","volume":"5","author":"Atanackovic","year":"2016","journal-title":"OncoImmunology"},{"issue":"10214","key":"10.1016\/j.ejphar.2026.178812_bib4","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study","volume":"394","author":"Attal","year":"2019","journal-title":"Lancet (London, England)"},{"issue":"2","key":"10.1016\/j.ejphar.2026.178812_bib5","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/cei.12935","article-title":"Fc\u03b3 receptor expression on splenic macrophages in adult immune thrombocytopenia","volume":"188","author":"Audia","year":"2017","journal-title":"Clin. Exp. Immunol."},{"issue":"6","key":"10.1016\/j.ejphar.2026.178812_bib6","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000574","article-title":"Immune thrombocytopenia: recent advances in pathogenesis and treatments","volume":"5","author":"Audia","year":"2021","journal-title":"HemaSphere"},{"key":"10.1016\/j.ejphar.2026.178812_bib7","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.3389\/fimmu.2019.01720","article-title":"NAD-biosynthetic and consuming enzymes as central players of metabolic regulation of innate and adaptive immune responses in cancer","volume":"10","author":"Audrito","year":"2019","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.ejphar.2026.178812_bib8","first-page":"187","article-title":"Platelet destruction in immune thrombocytopenia. Understanding the mechanisms","volume":"36","author":"Bakchoul","year":"2016","journal-title":"H\u00e4mostaseologie"},{"issue":"1","key":"10.1016\/j.ejphar.2026.178812_bib9","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1186\/s12967-024-05768-6","article-title":"CD38 as Theranostic target in oncology","volume":"22","author":"Bocuzzi","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.ejphar.2026.178812_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1499014","article-title":"The function of T cells in immune thrombocytopenia","volume":"16","author":"Bu","year":"2025","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.ejphar.2026.178812_bib11","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.3390\/ijms22052424","article-title":"Dysregulated CD38 expression on peripheral blood immune cell subsets in SLE","volume":"22","author":"Burns","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"6 Pt 2","key":"10.1016\/j.ejphar.2026.178812_bib12","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1111\/trf.13069","article-title":"Resolving the daratumumab interference with blood compatibility testing","volume":"55","author":"Chapuy","year":"2015","journal-title":"Transfusion"},{"issue":"23","key":"10.1016\/j.ejphar.2026.178812_bib14","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1056\/NEJMoa2400409","article-title":"A novel Anti-CD38 monoclonal antibody for treating immune thrombocytopenia","volume":"390","author":"Chen","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.ejphar.2026.178812_bib15","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1056\/NEJMoa2400409","article-title":"A novel Anti-CD38 monoclonal antibody for treating immune thrombocytopenia","volume":"390","author":"Chen","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2026.178812_bib16","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2025-084314","article-title":"Anti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: Multicentre, randomised, placebo controlled, phase 2 trial","volume":"391","author":"Chen","year":"2025","journal-title":"BMJ"},{"key":"10.1016\/j.ejphar.2026.178812_bib13","article-title":"Application of CD38 monoclonal antibody in kidney disease","volume":"15","author":"Chen","year":"2024","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.ejphar.2026.178812_bib17","doi-asserted-by":"crossref","first-page":"152","DOI":"10.2741\/4201","article-title":"CD38 and bone marrow microenvironment","volume":"19","author":"Chillemi","year":"2014","journal-title":"Front. Biosci. (Landmark Ed.)"},{"issue":"4","key":"10.1016\/j.ejphar.2026.178812_bib18","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.tips.2018.02.001","article-title":"The pharmacology of CD38\/NADase: an emerging target in cancer and diseases of aging","volume":"39","author":"Chini","year":"2018","journal-title":"Trends Pharmacol. Sci."},{"issue":"12","key":"10.1016\/j.ejphar.2026.178812_bib20","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.3390\/cells8121632","article-title":"CD38 expression by myeloma cells and its role in the context of bone marrow microenvironment: modulation by therapeutic agents","volume":"8","author":"Costa","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.ejphar.2026.178812_bib21","series-title":"DARZALEX\u00ae (Daratumumab) Approved by U.S. FDA: First Human Anti-CD38 Monoclonal Antibody Available for the Treatment of Multiple Myeloma","year":"2015"},{"issue":"1","key":"10.1016\/j.ejphar.2026.178812_bib22","doi-asserted-by":"crossref","first-page":"645","DOI":"10.3390\/ijms24010645","article-title":"Innovative Anti-CD38 and Anti-BCMA targeted therapies in multiple myeloma: mechanisms of action and resistance","volume":"24","author":"De Novellis","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.ejphar.2026.178812_bib23","doi-asserted-by":"crossref","first-page":"727","DOI":"10.4049\/jimmunol.156.2.727","article-title":"Human CD38 ligand. A 120-KDA protein predominantly expressed on endothelial cells","volume":"156","author":"Deaglio","year":"1996","journal-title":"Journal of Immunology (Baltimore, Md.: 1950)"},{"issue":"1","key":"10.1016\/j.ejphar.2026.178812_bib24","doi-asserted-by":"crossref","first-page":"395","DOI":"10.4049\/jimmunol.160.1.395","article-title":"Human CD38 (ADP-ribosyl cyclase) is a counter-receptor of CD31, an Ig superfamily member","volume":"160","author":"Deaglio","year":"1998","journal-title":"Journal of Immunology (Baltimore, Md.: 1950)"},{"issue":"17","key":"10.1016\/j.ejphar.2026.178812_bib25","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.1158\/1078-0432.CCR-14-0695","article-title":"SAR650984, a novel humanized CD38-Targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies","volume":"20","author":"Deckert","year":"2014","journal-title":"Clin. Cancer Res.: An Official Journal of the American Association for Cancer Research"},{"issue":"4","key":"10.1016\/j.ejphar.2026.178812_bib26","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.00225-23","article-title":"Cell-intrinsic CD38 expression sustains exhausted CD8+ T cells by regulating their survival and metabolism during chronic viral infection","volume":"97","author":"DeRogatis","year":"2023","journal-title":"J. Virol."},{"issue":"14","key":"10.1016\/j.ejphar.2026.178812_bib27","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.ejphar.2026.178812_bib28","doi-asserted-by":"crossref","first-page":"616","DOI":"10.3324\/haematol.2015.137620","article-title":"Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma","volume":"101","author":"Drent","year":"2016","journal-title":"Haematologica"},{"issue":"22","key":"10.1016\/j.ejphar.2026.178812_bib29","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.ejphar.2026.178812_bib30","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","article-title":"Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"391","author":"Facon","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2026.178812_bib31","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-83014-1","article-title":"Comprehensive safety evaluation of isatuximab in multiple myeloma using disproportionality analysis of FAERS and meta-analysis of randomized controlled trials","volume":"14","author":"Favas Karimbanathottathil","year":"2024","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.ejphar.2026.178812_bib32","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.3390\/jcm9041195","article-title":"Resistance mechanisms towards CD38\u2212Directed antibody therapy in multiple myeloma","volume":"9","author":"Franssen","year":"2020","journal-title":"J. Clin. Med."},{"issue":"1","key":"10.1016\/j.ejphar.2026.178812_bib33","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1399-0039.1997.tb02703.x","article-title":"Role of the human CD38 molecule in B cell activation and proliferation","volume":"49","author":"Funaro","year":"1997","journal-title":"Tissue Antigens"},{"issue":"6","key":"10.1016\/j.ejphar.2026.178812_bib34","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.3324\/haematol.2018.212845","article-title":"Thrombopoietin receptor agonists: ten years later","volume":"104","author":"Ghanima","year":"2019","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.ejphar.2026.178812_bib35","doi-asserted-by":"crossref","first-page":"228","DOI":"10.3390\/cells9010228","article-title":"Roles of CD38 in the immune response to infection","volume":"9","author":"Glar\u00eda","year":"2020","journal-title":"Cells"},{"issue":"16","key":"10.1016\/j.ejphar.2026.178812_bib36","doi-asserted-by":"crossref","first-page":"4418","DOI":"10.1182\/bloodadvances.2022007059","article-title":"CD38 as a pan-hematologic target for chimeric antigen receptor T cells","volume":"7","author":"Glisovic-Aplenc","year":"2023","journal-title":"Blood Adv."},{"issue":"16","key":"10.1016\/j.ejphar.2026.178812_bib37","doi-asserted-by":"crossref","first-page":"4418","DOI":"10.1182\/bloodadvances.2022007059","article-title":"CD38 as a pan-hematologic target for chimeric antigen receptor T cells","volume":"7","author":"Glisovic-Aplenc","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.ejphar.2026.178812_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104663","article-title":"Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity","volume":"93","author":"Hiemstra","year":"2023","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.ejphar.2026.178812_bib39","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1053\/j.seminoncol.2022.01.008","article-title":"Daratumumab: a review of current indications and future directions","volume":"49","author":"Hill","year":"2022","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ejphar.2026.178812_bib40","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3389\/fimmu.2018.00835","article-title":"Targeting B cells and plasma cells in autoimmune diseases","volume":"9","author":"Hofmann","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejphar.2026.178812_bib41","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.3389\/fimmu.2019.01187","article-title":"The multi-faceted ecto-enzyme CD38: roles in immunomodulation, cancer, aging, and metabolic diseases","volume":"10","author":"Hogan","year":"2019","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.ejphar.2026.178812_bib42","doi-asserted-by":"crossref","first-page":"4658","DOI":"10.1073\/pnas.1001074107","article-title":"Rituximab specifically depletes short-lived autoreactive plasma cells in a mouse model of inflammatory arthritis","volume":"107","author":"Huang","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"issue":"2","key":"10.1016\/j.ejphar.2026.178812_bib43","article-title":"Inhibition of CD38 enzymatic activity enhances CAR-T cell immune-therapeutic efficacy by repressing glycolytic metabolism","volume":"5","author":"Huang","year":"2024","journal-title":"Cell Rep. Med."},{"issue":"5","key":"10.1016\/j.ejphar.2026.178812_bib44","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1007\/s00277-020-04063-w","article-title":"Daratumumab for refractory warm autoimmune hemolytic anemia","volume":"100","author":"Jain","year":"2021","journal-title":"Ann. Hematol."},{"issue":"7","key":"10.1016\/j.ejphar.2026.178812_bib45","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.3390\/cells9071716","article-title":"CD38: t cell immuno-metabolic modulator","volume":"9","author":"Kar","year":"2020","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.ejphar.2026.178812_bib46","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ejphar.2026.178812_bib47","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-Cell expansion, and skews T-Cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2026.178812_bib48","article-title":"CD38: an important regulator of T cell function","volume":"153","author":"Li","year":"2022","journal-title":"Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie"},{"issue":"12","key":"10.1016\/j.ejphar.2026.178812_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2024.103677","article-title":"Autoimmune effector mechanisms associated with a defective immunosuppressive axis in immune thrombocytopenia (ITP)","volume":"23","author":"Li","year":"2024","journal-title":"Autoimmun. Rev."},{"issue":"10","key":"10.1016\/j.ejphar.2026.178812_bib50","doi-asserted-by":"crossref","first-page":"6541","DOI":"10.1097\/JS9.0000000000001814","article-title":"The role of immune cell signatures in the pathogenesis of ovarian-related diseases: a causal inference based on Mendelian randomization","volume":"110","author":"Lu","year":"2024","journal-title":"Int. J. Surg."},{"issue":"6","key":"10.1016\/j.ejphar.2026.178812_bib51","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.3324\/haematol.2019.218883","article-title":"Rituximab in the treatment of immune thrombocytopenia: what is the role of this agent in 2019?","volume":"104","author":"Lucchini","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.ejphar.2026.178812_bib52","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s40164-018-0119-4","article-title":"Daratumumab binds to mobilized CD34+ cells of myeloma patients in vitro without cytotoxicity or impaired progenitor cell growth","volume":"7","author":"Ma","year":"2018","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.ejphar.2026.178812_bib53","doi-asserted-by":"crossref","first-page":"494","DOI":"10.3389\/fimmu.2013.00494","article-title":"Long-lived plasma cells in autoimmunity: lessons from B-Cell depleting therapy","volume":"4","author":"Mah\u00e9vas","year":"2013","journal-title":"Front. Immunol."},{"issue":"20","key":"10.1016\/j.ejphar.2026.178812_bib54","first-page":"2417","article-title":"The role of CD8+ T-Cell clones in immune thrombocytopenia","volume":"141","author":"Malik","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ejphar.2026.178812_bib55","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12950-025-00457-7","article-title":"NAD + metabolism and function in innate and adaptive immune cells","volume":"22","author":"Mann","year":"2025","journal-title":"J. Inflamm."},{"issue":"3","key":"10.1016\/j.ejphar.2026.178812_bib56","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1055\/s-0039-1678732","article-title":"Pathophysiology of autoimmune thrombocytopenia: current insight with a focus on thrombopoiesis","volume":"39","author":"Marini","year":"2019","journal-title":"H\u00e4mostaseologie"},{"issue":"6","key":"10.1016\/j.ejphar.2026.178812_bib57","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ejphar.2026.178812_bib58","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa2400763","article-title":"A randomized phase 2 trial of felzartamab in antibody-mediated rejection","volume":"391","author":"Mayer","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ejphar.2026.178812_bib59","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2023-001112","article-title":"Mezagitamab in systemic lupus erythematosus: clinical and mechanistic findings of CD38 inhibition in an autoimmune disease","volume":"11","author":"McDonnell","year":"2024","journal-title":"Lupus Science & Medicine"},{"issue":"7","key":"10.1016\/j.ejphar.2026.178812_bib60","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3390\/ph15070779","article-title":"Novel therapies to address unmet needs in ITP","volume":"15","author":"Mingot-Castellano","year":"2022","journal-title":"Pharmaceuticals"},{"issue":"4","key":"10.1016\/j.ejphar.2026.178812_bib61","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.3390\/ijms25042163","article-title":"Current understanding of immune thrombocytopenia: a review of pathogenesis and treatment options","volume":"25","author":"Mititelu","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"10292","key":"10.1016\/j.ejphar.2026.178812_bib62","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/S0140-6736(21)00592-4","article-title":"Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial","volume":"397","author":"Moreau","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2026.178812_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2023.101141","article-title":"The many facets of immune-mediated thrombocytopenia: principles of immunobiology and immunotherapy","volume":"63","author":"Moulinet","year":"2024","journal-title":"Blood Rev."},{"issue":"7","key":"10.1016\/j.ejphar.2026.178812_bib64","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/nm1763","article-title":"The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis","volume":"14","author":"Neubert","year":"2008","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.ejphar.2026.178812_bib65","doi-asserted-by":"crossref","first-page":"250","DOI":"10.3324\/haematol.2020.248385","article-title":"Fc\u03b3RI and Fc\u03b3RIII on splenic macrophages mediate phagocytosis of anti-glycoprotein IIb\/IIIa autoantibody-opsonized platelets in immune thrombocytopenia","volume":"106","author":"Norris","year":"2020","journal-title":"Haematologica"},{"issue":"14","key":"10.1016\/j.ejphar.2026.178812_bib66","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1182\/bloodadvances.2022009423","article-title":"Serum from half of patients with immune thrombocytopenia trigger macrophage phagocytosis of platelets","volume":"7","author":"Norris","year":"2023","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.ejphar.2026.178812_bib67","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12929-019-0527-8","article-title":"Implications of altered NAD metabolism in metabolic disorders","volume":"26","author":"Okabe","year":"2019","journal-title":"J. Biomed. Sci."},{"issue":"12","key":"10.1016\/j.ejphar.2026.178812_bib68","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1056\/NEJMoa2023325","article-title":"Targeting CD38 with daratumumab in refractory systemic lupus erythematosus","volume":"383","author":"Ostendorf","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.ejphar.2026.178812_bib69","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ejphar.2026.178812_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2024.102345","article-title":"Immune attack on megakaryocytes in immune thrombocytopenia","volume":"8","author":"Petito","year":"2024","journal-title":"Research and Practice in Thrombosis and Haemostasis"},{"key":"10.1016\/j.ejphar.2026.178812_bib71","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.597959","article-title":"CD38: an immunomodulatory molecule in inflammation and autoimmunity","volume":"11","author":"Piedra-Quintero","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejphar.2026.178812_bib72","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13059-016-0939-7","article-title":"Single-cell profiling of human megakaryocyte-erythroid progenitors identifies distinct megakaryocyte and erythroid differentiation pathways","volume":"17","author":"Psaila","year":"2016","journal-title":"Genome Biol."},{"issue":"4","key":"10.1016\/j.ejphar.2026.178812_bib73","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/cyto.b.21092","article-title":"CD38 and CD157: a long journey from activation markers to multifunctional molecules","volume":"84","author":"Quarona","year":"2013","journal-title":"Cytom., Part B Clin. Cytom."},{"issue":"3","key":"10.1016\/j.ejphar.2026.178812_bib74","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41408-021-00438-y","article-title":"Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed\/refractory multiple myeloma","volume":"11","author":"Richardson","year":"2021","journal-title":"Blood Cancer J."},{"issue":"11","key":"10.1016\/j.ejphar.2026.178812_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113312","article-title":"Mitochondrial gene expression is required for platelet function and blood clotting","volume":"42","author":"Richman","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejphar.2026.178812_bib76","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.662223","article-title":"Bruton's tyrosine kinase (BTK) inhibitors and autoimmune diseases: making sense of BTK inhibitor specificity profiles and recent clinical trial successes and failures","volume":"12","author":"Ringheim","year":"2021","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.ejphar.2026.178812_bib77","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/bjh.18818","article-title":"Assessment of circulating blood lymphocytes in adult patients on rituximab to treat immune thrombocytopenia: circulating number of NK cells is associated with the response at 6 months","volume":"202","author":"Rivi\u00e8re","year":"2023","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.ejphar.2026.178812_bib78","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/bjh.18773","article-title":"B cells and antibodies in refractory immune thrombocytopenia","volume":"203","author":"Roeser","year":"2023","journal-title":"Br. J. Haematol."},{"issue":"9","key":"10.1016\/j.ejphar.2026.178812_bib79","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1016\/j.ekir.2024.06.018","article-title":"Phase 1b\/2a study assessing the safety and efficacy of felzartamab in anti-phospholipase A2 receptor autoantibody-positive primary membranous nephropathy","volume":"9","author":"Rovin","year":"2024","journal-title":"Kidney Int. Rep."},{"issue":"7","key":"10.1016\/j.ejphar.2026.178812_bib80","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1182\/blood-2016-01-693705","article-title":"Adult human megakaryocyte-erythroid progenitors are in the CD34+CD38mid fraction","volume":"128","author":"Sanada","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ejphar.2026.178812_bib81","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2141.2009.07615.x","article-title":"Epidemiology of immune thrombocytopenic purpura in the general practice research database","volume":"145","author":"Schoonen","year":"2009","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/j.ejphar.2026.178812_bib82","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.ejphar.2026.178812_bib83","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1002\/cam4.2827","article-title":"Daratumumab Prevents Programmed Death Ligand\u20101 Expression on Antigen\u2010presenting Cells in de Novo Multiple Myeloma","volume":"9","author":"Stocker","year":"2020","journal-title":"Cancer Med."},{"issue":"4","key":"10.1016\/j.ejphar.2026.178812_bib84","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1038\/s41591-024-03485-7","article-title":"Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial","volume":"31","author":"Usmani","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2026.178812_bib85","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.3389\/fimmu.2018.02134","article-title":"CD38 antibodies in multiple myeloma: mechanisms of action and modes of resistance","volume":"9","author":"van de Donk","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejphar.2026.178812_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcmd.2023.102724","article-title":"Daratumumab as a novel treatment option in refractory ITP","volume":"99","author":"Vernava","year":"2023","journal-title":"Blood Cell Mol. Dis."},{"issue":"1","key":"10.1016\/j.ejphar.2026.178812_bib87","doi-asserted-by":"crossref","first-page":"58","DOI":"10.4331\/wjbc.v5.i1.58","article-title":"Roles and mechanisms of the CD38\/Cyclic adenosine diphosphate Ribose\/Ca2+ signaling pathway","volume":"5","author":"Wei","year":"2014","journal-title":"World J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.ejphar.2026.178812_bib88","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.7150\/ijbs.68148","article-title":"Regulation of CD38 on multiple myeloma and NK cells by monoclonal antibodies","volume":"18","author":"Wu","year":"2022","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.ejphar.2026.178812_bib89","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1215216","article-title":"Rituximab resistance in ITP and beyond","volume":"14","author":"Xiao","year":"2023","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.ejphar.2026.178812_bib90","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1093\/abt\/tbab022","article-title":"Development of a reporter gene method to measure the bioactivity of Anti-CD38 \u00d7 CD3 bispecific antibody","volume":"4","author":"Xiong","year":"2021","journal-title":"Antibody Therapeutics"},{"issue":"8","key":"10.1016\/j.ejphar.2026.178812_bib91","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/s41423-022-00881-2","article-title":"ADAP restraint of STAT1 signaling regulates macrophage phagocytosis in immune thrombocytopenia","volume":"19","author":"Xiong","year":"2022","journal-title":"Cell. Mol. Immunol."},{"issue":"3","key":"10.1016\/j.ejphar.2026.178812_bib92","doi-asserted-by":"crossref","first-page":"768","DOI":"10.3390\/cells9030768","article-title":"NK cells and CD38: implication for (immuno)Therapy in plasma cell dyscrasias","volume":"9","author":"Zambello","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.ejphar.2026.178812_bib93","article-title":"Unveiling the role of NAD glycohydrolase CD38 in aging and age-related diseases: insights from bibliometric analysis and comprehensive review","volume":"16","author":"Zhao","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejphar.2026.178812_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.107803","article-title":"The metabolism-immunity axis in immune thrombocytopenia: from energy regulation to targeted therapy","volume":"217","author":"Zhou","year":"2025","journal-title":"Pharmacol. Res."},{"issue":"8","key":"10.1016\/j.ejphar.2026.178812_bib95","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.3324\/haematol.2018.204446","article-title":"All-trans retinoic acid protects mesenchymal stem cells from immune thrombocytopenia by regulating the Complement-Interleukin-1\u03b2 loop","volume":"104","author":"Zhu","year":"2019","journal-title":"Haematologica"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926002943?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926002943?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T21:49:57Z","timestamp":1776116997000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299926002943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":94,"alternative-id":["S0014299926002943"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.178812","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Precision targeting of CD38 in immune thrombocytopenia: Mechanistic foundations and therapeutic implications","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.178812","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"178812"}}